North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin‐induced peripheral neuropathy: A phase 3 randomized, double‐blind, placebo‐controlled study

Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant side effect of taxane and platinum‐based chemotherapy. Several studies have supported the potential benefit of glutathione for the prevention of platinum‐induced CIPN. The current trial was designed to determine whether glutathione would prevent CIPN as a result of carboplatin/paclitaxel therapy.

[1]  C. Loprinzi,et al.  Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Hortobagyi,et al.  Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Shapiro,et al.  Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. , 2013, JAMA.

[4]  P. Novotny,et al.  Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy , 2012, Cancer.

[5]  P. Dougherty,et al.  Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. , 2012, The journal of pain : official journal of the American Pain Society.

[6]  J. Sloan,et al.  The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial , 2011, Supportive Care in Cancer.

[7]  C. Saab,et al.  Minocycline injection in the ventral posterolateral thalamus reverses microglial reactivity and thermal hyperalgesia secondary to sciatic neuropathy , 2011, Neuroscience Letters.

[8]  K. Dua,et al.  Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. , 2011, European journal of pharmacology.

[9]  X. Mei,et al.  Post-injury administration of minocycline: An effective treatment for nerve-injury induced neuropathic pain , 2011, Neuroscience Research.

[10]  P. Novotny,et al.  Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Dougherty,et al.  Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline , 2011, PAIN®.

[12]  Jin-Ho Song,et al.  Effects of minocycline on Na+ currents in rat dorsal root ganglion neurons , 2011, Brain Research.

[13]  B. Przewłocka,et al.  Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain , 2010, Neuroscience.

[14]  Tao Yang,et al.  Prevention of Paclitaxel-induced allodynia by Minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats , 2010, Molecular pain.

[15]  R. Hurlbert,et al.  Neuroprotection with Minocycline after Spinal Cord Injury: Results of a Double Blind, Randomized, Controlled Pilot Study 929 , 2009, Neurosurgery.

[16]  S. McMahon,et al.  Effects of Etanercept and Minocycline in a rat model of spinal cord injury , 2009, European journal of pain.

[17]  U. Jaehde,et al.  Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity , 2009, Anti-cancer drugs.

[18]  S. Kulkarni,et al.  Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. , 2008, European journal of pharmacology.

[19]  W. Schäbitz,et al.  MINOCYCLINE TREATMENT IN ACUTE STROKE: AN OPEN-LABEL, EVALUATOR-BLINDED STUDY , 2007, Neurology.

[20]  P. Dougherty,et al.  The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats , 2008, Brain Research.

[21]  S. Jung,et al.  Systemic administration of minocycline inhibits formalin-induced inflammatory pain in rat , 2006, Brain Research.

[22]  Po-min Chen,et al.  N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data , 2006, Supportive Care in Cancer.

[23]  S. Maier,et al.  Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation , 2005, Pain.

[24]  C. Power,et al.  For Personal Use. Only Reproduce with Permission from Elsevier Ltd Minocycline and Neurological Diseases Minocycline in Animal Models the Promise of Minocycline in Neurology , 2022 .

[25]  L. Vahdat,et al.  Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies , 2004, Supportive Care in Cancer.

[26]  G. Bennett,et al.  Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy , 2004, Pain.

[27]  J. Steeves,et al.  Minocycline Treatment Reduces Delayed Oligodendrocyte Death, Attenuates Axonal Dieback, and Improves Functional Outcome after Spinal Cord Injury , 2004, The Journal of Neuroscience.

[28]  H. Diener,et al.  Lack of neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma , 2004, Journal of Cancer Research and Clinical Oncology.

[29]  J. Deleo,et al.  Inhibition of Microglial Activation Attenuates the Development but Not Existing Hypersensitivity in a Rat Model of Neuropathy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[30]  P. Novotny,et al.  Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy , 2002, Pain.

[31]  D. Cella,et al.  Reliability and validity of the functional assessment of cancer therapy-ovarian. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Bennett,et al.  Chemotherapy-evoked painful peripheral neuropathy. , 2001, Pain medicine (Malden, Mass.).

[33]  C. Oliveira,et al.  Oxidative glutamate toxicity involves mitochondrial dysfunction and perturbation of intracellular Ca2+ homeostasis , 2000, Neuroscience Research.

[34]  E. Jenison,et al.  A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. , 1997, Gynecologic oncology.

[35]  R. Prescott,et al.  Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  P. Diggle.  Analysis of Longitudinal Data , 1995 .

[37]  J. Neijt,et al.  The effects of an ACTH (4–9) analogue on development of cisplatin neuropathy in testicular cancer: A randomized trial , 1994, Journal of Neurology.

[38]  G. Cavaletti,et al.  Protective effects of glutathione on cisplatin neurotoxicity in rats. , 1994, International journal of radiation oncology, biology, physics.

[39]  G. Cavaletti,et al.  Weekly cisplatin ± glutathione in relapsed ovarian carcinoma , 1994, International Journal of Gynecologic Cancer.

[40]  G. Cavaletti,et al.  Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione , 1992, The Italian Journal of Neurological Sciences.

[41]  J. Heimans,et al.  A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy. , 1992, Archives of neurology.

[42]  D. Stewart,et al.  Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  W. van Putten,et al.  The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo , 1992, Journal of Neurology.

[44]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[45]  J. van Houwelingen,et al.  Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer , 1990, The New England journal of medicine.

[46]  J. C. Houwelingen,et al.  Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer , 1990 .

[47]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[48]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[49]  E. Raymond,et al.  Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  U. Chaudhary,et al.  Long-Term Complications of Chemotherapy for Germ Cell Tumours , 2012, Drugs.

[51]  Jan J. Heimans,et al.  Neurotoxic Complications of Chemotherapy in Patients with Cancer , 2012, Drugs.

[52]  I. Barajon,et al.  Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats , 2004, Acta Neuropathologica.

[53]  Tapabrata Maiti,et al.  Analysis of Longitudinal Data (2nd ed.) (Book) , 2004 .

[54]  R. Labianca,et al.  Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  S. Cascinu,et al.  Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Hughes,et al.  Peripheral neuropathy. , 1982, The New England journal of medicine.

[57]  D.,et al.  Regression Models and Life-Tables , 2022 .